

Edgar Filing: ALLERGAN INC - Form 10-K405

ALLERGAN INC
Form 10-K405
March 23, 2001

1

FORM 10-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2000

COMMISSION FILE NO. 1-10269

ALLERGAN, INC.

(Exact name of Registrant as Specified in its Charter)

DELAWARE
(State of Incorporation)

95-1622442
(I.R.S. Employer
Identification No.)

2525 DUPONT DRIVE
IRVINE, CALIFORNIA
(Address of principal executive offices)

92612
(Zip Code)

Registrant's telephone number: (714) 246-4500

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which each class registered
Common Stock, \$0.01 par value Preferred Share Purchase Rights	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:

NONE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.

Yes X No
----- -----

The aggregate market value of the registrant's voting stock held by non-affiliates was approximately \$10,977,000,000 on January 26, 2001, based upon the closing price on the New York Stock Exchange on such date.

Common Stock outstanding as of January 26, 2001 - 134,254,772 shares (including 2,486,079 shares held in treasury).

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any

Edgar Filing: ALLERGAN INC - Form 10-K405

amendment to this Form 10-K. [X]

DOCUMENTS INCORPORATED BY REFERENCE

Parts I, II, III and IV incorporate certain information by reference from the registrant's proxy statement for the annual meeting of stockholders to be held on April 25, 2001, which proxy statement was filed with the Securities and Exchange Commission on March 23, 2001.

2

TABLE OF CONTENTS

	PAGE
PART I	
Item 1. Business.....	1
Item 2. Properties.....	13
Item 3. Legal Proceedings.....	13
Item 4. Submission of Matters to a Vote of Security Holders.....	14
Item I-A. Executive Officers of Allergan, Inc.....	14
PART II	
Item 5. Market for Registrant's Common Equity and Related Stockholder Matters.....	17
Item 6. Selected Financial Data.....	17
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.....	17
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.....	17
Item 8. Financial Statements and Supplementary Data.....	17
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.....	17
PART III	
Item 10. Directors and Executive Officers of Allergan, Inc.....	18
Item 11. Executive Compensation	18
Item 12. Security Ownership of Certain Beneficial Owners and Management.....	18
Item 13. Certain Relationships and Related Transactions.....	18
PART IV	
Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K.....	19
SIGNATURES	S-1
INDEX OF EXHIBITS	S-3
SCHEDULE	S-8
EXHIBITS	(Attached to this Report on Form 10-K)

3

Edgar Filing: ALLERGAN INC - Form 10-K405

PART I

ITEM 1. BUSINESS

GENERAL DEVELOPMENT OF BUSINESS

Allergan, Inc. ("Allergan" or the "Company") is a provider of eye care and specialty pharmaceutical products throughout the world with products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets. Its worldwide consolidated revenues are principally generated by prescription and non-prescription pharmaceutical products in the areas of ophthalmology and skin care, neurotoxins, intraocular lenses and other ophthalmic surgical products, and contact lens care products.

Allergan was originally incorporated in California in 1948, became known as Allergan Corporation in 1950, and reincorporated in Delaware in 1977. In 1980, the Company was acquired by SmithKline Beecham plc (then known as "SmithKline Corporation" and herein "SmithKline"). The Company operated as a wholly-owned subsidiary of SmithKline from 1980 until 1989 when Allergan again became a stand-alone public company through a spin-off distribution by SmithKline.

On December 9, 1999 the Company implemented a two-for-one stock split effected as a dividend to stockholders of record on November 18, 1999. All historical information contained in this report has been adjusted to reflect the 1999 stock split.

ALLERGAN BUSINESSES

The following table sets forth, for the periods indicated, the net sales from continuing operations for each of the Company's specialty therapeutics businesses and product lines:

	YEAR ENDED DECEMBER 31		
	2000	1999	1998
	----	----	----
	(IN MILLIONS)		
Specialty Pharmaceuticals:			
Eye Care Pharmaceuticals	\$ 675.3	\$ 571.2	\$ 505.3
Skin Care	68.7	76.6	80.6
Botox(R)/Neuromuscular	239.5	175.8	125.3
	-----	-----	-----
Total	983.5	823.6	711.2
Medical Devices and OTC Product Lines:			
Ophthalmic Surgical	250.4	222.9	193.6
Contact Lens Care	328.7	359.7	356.9
	-----	-----	-----
Total	579.1	582.6	550.5
Total Product Net Sales	\$1,562.6	\$1,406.2	\$1,261.7
	=====	=====	=====
Domestic	51.7%	48.1%	46.2%
International	48.3%	51.9%	53.8%

Edgar Filing: ALLERGAN INC - Form 10-K405

See Note 14 of Notes to Consolidated Financial Statements on pages A-36 to A-37 of the Company's Proxy Statement filed on March 23, 2001 for further information concerning foreign and domestic operations.

1

4

SPECIALTY PHARMACEUTICAL BUSINESS

Eye Care Pharmaceutical Product Line

Allergan develops, manufactures and markets a broad range of prescription and non-prescription products designed to treat diseases and disorders of the eye, including glaucoma, inflammation, infection and allergy. In addition, the specialty over-the-counter product line consists of products designed to treat ocular surface disease, including artificial tears and ocular decongestants.

GLAUCOMA

The largest segment of the market for ophthalmic prescription drugs is for the treatment of glaucoma, a sight-threatening disease characterized by elevated intraocular pressure leading to optic nerve damage. Allergan's largest selling eye care pharmaceutical product is Alphagan(R) ophthalmic solution, which was approved by the United States Food and Drug Administration ("FDA") in September 1996 for the treatment of open-angle glaucoma and ocular hypertension. Sales of Alphagan(R) ophthalmic solution represented 15%, 12% and 9% of total Company sales in 2000, 1999 and 1998, respectively. The period of new chemical entity exclusivity in the United States for Alphagan(R) ophthalmic solution extends for five years from the date of approval. Allergan sells Alphagan(R) ophthalmic solution in 69 countries worldwide.

Allergan filed two new drug applications ("NDAs") with the FDA in 2000 for glaucoma products. In the third quarter of 2000, Allergan filed an NDA in the U.S. and in the fourth quarter of 2000 filed a Marketing Authorization Application ("MAA") in Europe for Lumigan(TM), a topical treatment for elevated intraocular pressure in patients with glaucoma or ocular hypertension. The FDA approved Lumigan(TM) in March 2001 for the reduction of elevated intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication. The second NDA was for Alphagan(R) P, a reformulation containing brimonodine, the active ingredient in Alphagan(R) ophthalmic solution, preserved with Purite(R). The FDA also approved Alphagan(R) P in March 2001 for the lowering of IOP in patients with open-angle glaucoma and ocular hypertension. Alphagan(R) P ophthalmic solution lowers IOP by reducing aqueous humor production and increasing uveoscleral outflow, while data suggests that Lumigan(TM) ophthalmic solution lowers IOP by increasing the outflow of aqueous humor through trabecular meshwork and uveoscleral routes. The Company intends to launch both products in 2001.

The Company also markets Betagan(R) ophthalmic solution, a topical beta blocker used in the treatment of glaucoma, and Propine(R) ophthalmic solution, which is used alone or in combination with other drugs when initial drug therapy for glaucoma becomes inadequate. Patent protection for both products expired in the United States in 1991 and they both face generic competition from several companies including Bausch & Lomb and Alcon Laboratories, Inc. (a division of Nestle). In addition, the Company markets its own generic version of these two products.

INFLAMMATION

Edgar Filing: ALLERGAN INC - Form 10-K405

Allergan's leading ophthalmic anti-inflammatory product is Acular(R) (1) ophthalmic solution. It is indicated for the relief of itch associated with seasonal allergic conjunctivitis and for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Acular(R) PF was the first unit-dose, preservative-free topical nonsteroidal anti-

(1) Acular(R) is a registered trademark of and is licensed from its developer Syntex (U.S.A.) Inc.

2

5

inflammatory drug (NSAID) in the United States, and is indicated for the reduction of ocular pain and photophobia following incisional refractive surgery. Pred Forte(R) and FML(R) Liquifilm(R) ophthalmic suspensions are Allergan's products in the ocular corticosteroid inflammation market.

INFECTION

Allergan's major products in the anti-infective market are Ocuflax(R)/Oflox(R)/Exocin(R) ophthalmic solution, a fluoroquinolone which treats bacterial conjunctivitis and corneal ulcers, Blephamide(R) ophthalmic suspension, a topical anti-inflammatory and anti-infective, and Polytrim(R) ophthalmic solution, a synthetic antimicrobial which treats surface ocular bacterial infections. Blephamide(R), Pred Forte(R) and Polytrim(R) ophthalmic solutions no longer have patent protection and face generic competition. McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, is Allergan's marketing partner for Ocuflax(R) ophthalmic solution in the U.S. pediatric and selected general practitioner markets.

ALLERGY

Allergan launched Alocril(R) ophthalmic solution in early 2000. Alocril(R) is indicated for the treatment of itch associated with allergic conjunctivitis. The allergy market, is by its nature, a seasonal market, peaking during the Spring months.

OCULAR SURFACE DISEASE

In addition to its eye care pharmaceuticals, Allergan markets a variety of artificial tear products for various needs, under a range of brand names worldwide, led by the Refresh(R) brand. In the United States, the Refresh(R) brand includes Refresh Plus(R), Refresh Tears(R), and Refresh P.M.(R) Allergan also markets Celluvisc(R) in the United States for severe dry eye. Other Allergan brands marketed around the world include the, Liquifilm Tears(R) and Lacri-Lube(R) S.O.P.(R) products as well as Lerin(R), a decongestant.

Allergan has filed an NDA and an MAA for Restasis(TM), a prescription ophthalmic emulsion product for the treatment of chronic dry eye disease. In 2001, Allergan plans to initiate a six-month confirmatory study to support these applications.

Skin Care Product Line

Allergan's skin care business is currently comprised of three main product lines: tazarotene products in cream and gel formulations marketed under

Edgar Filing: ALLERGAN INC - Form 10-K405

Tazorac(R) in the United States and Canada and as Zorac(R) elsewhere; Azelex(R), an acne product; and the M.D. Forte(R) line of alpha hydroxy acid products. Allergan promotes its skin care products primarily in the United States.

In June 1997, the Company received approval from the FDA to market Tazorac(R) gel for the treatment of plaque psoriasis and acne. The FDA approved the cream formulation of Tazorac(R) in October 2000 for the treatment of psoriasis. Allergan filed a Supplemental NDA in December 2000 for the acne indication of Tazorac(R) cream. Allergan promotes Tazorac(R) in the United States, along with its co-promotion partner, 3M Pharmaceuticals. Outside of the U.S., Allergan has engaged Pierre Fabre Dermatologie and Bioglan Pharma PLC as its promotion partners for Zorac(R) in Europe, the Middle East and Africa.

Azelex(R) cream is approved for the topical treatment of mild to moderate inflammatory acne vulgaris. Allergan launched Azelex(R) cream in the U.S. in December 1995.

3

6

The Company also develops and markets glycolic acid-based skin care products. In 1999, the Company divested its aesthetician salon and retail-based alpha hydroxy acid products as part of an initiative to focus on the M.D. Forte(R) line of alpha hydroxy acid products. M.D. Forte(R) products are marketed to and dispensed by physicians.

Botox(R)/Neuromuscular

Allergan's Botox(R) (Botulinum Toxin Type A) Purified Neurotoxin Complex is used in the treatment of certain neuromuscular disorders which are characterized by involuntary muscle contractions or spasms. Sales of Botox(R) Purified Neurotoxin Complex represented 15%, 13% and 10% of total Company sales in 2000, 1999 and 1998, respectively. The Company markets Botox(R) Purified Neurotoxin Complex in the United States and in 66 other countries.

The approved indications for Botox(R) in the United States are for the treatment of blepharospasm (the uncontrollable contraction of the eyelid muscles which can force the eye closed and result in functional blindness); strabismus (misalignment of the eyes) in people 12 years of age and over; and cervical dystonia in adults (along with the associated pain). Outside of the U.S., Botox(R) Purified Neurotoxin Complex is also approved for hemifacial spasm, pediatric cerebral palsy and upper limb spasticity associated with debilities occurring after a stroke.

The Company is pursuing new approved indications for Botox(R) Purified Neurotoxin Complex, including brow furrow, pediatric cerebral palsy, headache, hyperhidrosis (excessive sweating), back spasm, spasticity, anal fissure and temporal mandibular joint disease.

The Company manufactures bulk toxin raw material necessary to produce Botox(R) Purified Neurotoxin Complex. The process to create bulk toxin is technically complicated and difficult. Any failure of the Company to maintain an adequate supply of bulk toxin could result in an interruption in the supply of Botox(R) Purified Neurotoxin Complex with a resulting decrease in sales of the product.

MEDICAL DEVICES AND OTC PRODUCT LINES

Ophthalmic Surgical Product Line

Allergan's ophthalmic surgical business develops, manufactures and

Edgar Filing: ALLERGAN INC - Form 10-K405

markets intraocular lenses ("IOLs"), surgically related pharmaceuticals, phacoemulsification equipment and other ophthalmic refractive surgical products.

The largest segment of the surgical market is for the treatment of cataracts. Cataracts are a condition, usually age related, in which the natural lens of the eye becomes progressively clouded. This clouding obstructs the passage of light and can eventually lead to blindness. Most patients affected by cataracts can be surgically treated by removing the clouded lens and replacing it with an IOL. The Company currently offers a line of products used in the performance of cataract surgery, including silicone monofocal and multi-focal IOLs, an acrylic IOL and PMMA IOLs.

Sales of all models of the Company's IOLs represented 11% of total Company sales in each of 2000 and 1999 and 10% of total Company sales in 1998. Foldable IOLs marketed by Allergan for small incision cataract surgery include the Array(R) multifocal silicone IOL; its line of monofocal silicone IOLs (PhacoflexII(R)SI-30NB(R), SI-40NB(R), and PhacoflexII(R)SI-55NB(R)); and the Sensor(R) acrylic IOL, which was introduced in Europe in 1998 and was approved for marketing in the United States in February 2000. Along with foldable IOLs, the Company also markets a series of insertion systems for each of its foldable lens models,

4

7

referred to as The UnFolder(R) implantation systems. The systems assist the surgeon in achieving controlled release of the IOL in incisions as small as 2.8 mm.

Phacoemulsification is a method of cataract extraction that uses ultrasound waves to break the natural lens into small fragments that can be removed through a hollow needle. Allergan currently markets the Prestige(R), AMO(R)Diplomax(R) and Sovereign(TM) phacoemulsification systems. Allergan also markets AMO(R)Vitrax(R), a viscoelastic used to maintain the anterior chamber and protect endothelial cells during cataract surgery. And, in 1998, the Company became a distributor of BioLon(TM)2 viscoelastic in the United States under an agreement with Akorn, Inc. The Company has partnered with Allegiance Healthcare Corporation to provide custom surgical procedure packs to its U.S. and European customers.

In 2000, Allergan entered the refractive surgery market with the Amadeus(R) microkeratome. Surgeons use microkeratomes in LASIK procedures to cut a flap of corneal tissue that is folded back during the laser procedure and then folded back to its original position. Allergan is the exclusive worldwide distributor of the Amadeus(R) microkeratome and SurePass(R) microkeratome blades, which are manufactured by SIS AG, Surgical Instrument Systems in Switzerland. Allergan also has a U.S. co-marketing agreement with VISX Incorporated, which sells excimer laser systems for vision correction.

Contact Lens Care Product Line

The Company has been active in the contact lens care market since 1960. On a worldwide basis, it develops, manufactures and markets a broad range of products for use with every available type of contact lens. These products include disinfecting solutions to destroy harmful microorganisms in and on the surface of contact lenses; daily cleaners to remove undesirable film and deposits from contact lenses; enzymatic cleaners to remove protein deposits from contact lenses; and lens rewetting drops to provide added wearing comfort.

In the area of disinfecting products for soft contact lenses, the Company offers products that can be used in both the hydrogen peroxide and

Edgar Filing: ALLERGAN INC - Form 10-K405

convenient chemical systems. Allergan's leading hydrogen peroxide system products are the Oxysept 1Step(R)/UltraCare(R) hydrogen peroxide neutralizer/disinfection system, with a color indicator which turns the solution pink to indicate the disinfectant tablet has dissolved. Complete(R) brand Multi-Purpose solution is the Company's convenient, one-bottle chemical disinfection system for soft contact lenses. The Company currently markets Complete(R) brand Multi-Purpose solution worldwide, including Japan as of 1999. Complete(R) brand ComfortPLUS(TM) Multi-Purpose solution, the Company's latest product upgrade, contains a proprietary comfort formulation for longer, more comfortable contact lens wear.

In November 1995, the Company acquired the worldwide contact lens care business of Pilkington Barnes Hind. Included in the acquisition was the Consept F(R) Cleaning and Disinfecting System, the first approved non-heat disinfection system for soft contact lenses in Japan. This acquisition significantly increased the Company's contact lens care product business in Japan.

In 2000 Allergan launched a new eye drop for contact lens wearers called Refresh Contacts(R) to help provide comfort and protection from dryness and irritation.

Also in 2000, Allergan entered into a strategic global alliance with the Vistakon Division of Johnson & Johnson Vision Care, Inc., makers of the Acuvue(R) brand contact lenses. This alliance includes research, educational, marketing, and co-detailing initiatives.

5

8

Sales of the Company's hydrogen peroxide disinfection systems represented 5%, 7% and 10% of total Company sales in 2000, 1999 and 1998, respectively. The Company's Contact Lens Care business continues to be impacted by trends in the contact lens and lens care marketplace, including technological and medical advances in surgical techniques for the correction of vision impairment. Cheaper one-bottle chemical disinfection systems have gained popularity among soft contact lens wearers instead of peroxide-based lens care products which have historically been Allergan's strongest family of lens care products. The Company's primary strategy is to focus its sales and marketing resources on aggressive growth of Complete(R) brand Multi-Purpose solution which grew faster than its segment on a worldwide basis in 2000. Also, the growing use and acceptance of daily contact lenses, along with the other factors above, could have the effect of reducing demand for lens care products generally. While the Company believes it has established appropriate marketing and sales plans to mitigate the impact of these trends upon its Contact Lens Care business, no assurance can be given in this regard.

EMPLOYEE RELATIONS

At December 31, 2000, the Company employed 6,181 persons throughout the world, including 2,308 in the United States. None of the Company's U.S.-based employees are represented by unions. The Company considers that its relations with its employees are, in general, very good.

INTERNATIONAL OPERATIONS

Allergan's international sales have represented approximately 48.3%, 51.9% and 53.8% of total sales for the years ended December 31, 2000, 1999 and 1998, respectively. Allergan established its first foreign subsidiary in 1964 and the Company's products are sold in approximately 120 countries. Marketing activities are coordinated on a worldwide basis, and resident management teams provide leadership and infrastructure for customer focused rapid introduction of

Edgar Filing: ALLERGAN INC - Form 10-K405

new products in the local markets.

SALES AND MARKETING

Allergan maintains a global marketing team, as well as regional sales and marketing organizations. Allergan's sales efforts and promotional activities are primarily aimed at eye care professionals, as well as neurologists and dermatologists, who use, prescribe and recommend its products. In addition, Allergan advertises in professional journals and has an extensive direct mail program of descriptive product literature and scientific information to specialists in the ophthalmic, dermatological and movement disorder fields. The Company has also developed training modules and seminars to update physicians regarding evolving technology. Allergan has also utilized direct-to-consumer advertising of its contact lens care products, Refresh(R) products and Array(R) multifocal silicone IOL.

The Company's products are sold to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, ambulatory surgery centers and medical practitioners, including neurologists, dermatologists and plastic surgeons. At December 31, 2000, the Company employed approximately 1,600 sales representatives throughout the world. The Company also utilizes distributors for its products in the smaller international markets.

6

9

RESEARCH AND DEVELOPMENT

The Company's global research and development efforts focus on eye care, skin care and neuromuscular products that are safe, effective, convenient and have an economic benefit. The Company's own research and development activities are supplemented by a commitment to identifying and obtaining new technologies through in-licensing, technological collaborations, joint ventures and acquisition efforts, including the establishment of research relationships with academic institutions and individual researchers.

At December 31, 2000, there were, in the aggregate, approximately 1,000 people involved in the Company's research and development efforts. The Company's research and development expenditures for 2000, 1999 and 1998 were \$195.6 million, \$168.4 million and \$125.4 million, respectively, excluding amounts spent by the Company on behalf of Allergan Specialty Therapeutics, Inc.

Research and development efforts for the ophthalmic pharmaceuticals business focus primarily on new therapeutic products for glaucoma, inflammation, retinal diseases, dry eye, allergy and new anti-infective pharmaceuticals for eye care. Below is a summary of major research and development projects in the ophthalmic pharmaceutical segment:

- In its glaucoma research, the Company is pursuing two approaches. The first is to improve upon agents for lowering intraocular pressure, and the second is to develop drugs that directly protect the optic nerve.
- In the retinal disease area, Allergan is continuing programs to treat age-related macular degeneration.
- Allergan continues to pursue ocular allergy, anti-inflammatory and anti-infective products.

Research and development activities for the surgical business concentrate on improved cataract surgical systems, implantation instruments and

Edgar Filing: ALLERGAN INC - Form 10-K405

methods, and new IOL materials and designs.

For the skin care business, Allergan's research and development team is working on expanded indications and formulations for tazarotene. The team is also working on an anti-acne approach based on enzyme inhibitors.

Research and development efforts for neuromuscular disorders focus on expanding the uses for Botox(R) (Botulinum Toxin Type A) Purified Neurotoxin Complex to include treatment for pediatric cerebral palsy, spasticity, headache, lower back pain, anal fissure, brow furrow, hyperhidrosis and temporal mandibular joint disease. Allergan is also pursuing new toxin based products.

Research and development in the contact lens care business is aimed at systems that are effective and more convenient for patients to use, and thus lead to a higher rate of compliance with recommended lens care procedures. Improved compliance can enhance safety and extend the time a patient will be a contact lens wearer.

Allergan is also working to leverage its technologies in therapeutic areas outside of its current specialites, such as the use of its receptor-selective retinoid technology in therapeutic areas such as cancer, diabetes, dyslipidermia and bone disease and alpha agonists in the treatment of neuropathic pain.

In 1997 the Company formed a new subsidiary, Allergan Specialty Therapeutics, Inc. ("ASTI"), to conduct research and development of potential pharmaceutical products based on the Company's retinoid and neuroprotective technologies. In March 1998, the Company distributed all ASTI Class A Common Stock to the Company's stockholders, who

7

10

received one share of ASTI Class A Common Stock for each 20 shares of Allergan common stock held as of the record date.

As the sole holder of ASTI's outstanding Class B Common Stock following the distribution and under the terms of ASTI's Restated Certificate of Incorporation, the Company has the option to repurchase all of the outstanding shares of ASTI Class A Common Stock under specified conditions. Under the terms of a technology license agreement and a license option agreement between the Company and ASTI, the Company has also granted certain technology licenses and agreed to make specified payments on sales of certain products in exchange for the payment by ASTI of a technology fee and the option to independently develop certain compounds funded by ASTI prior to the filing of an Investigational New Drug application with the FDA with respect thereto and to license any products and technology developed by ASTI. The Company will recognize the technology fee as revenue as it is earned and received.

ASTI's technology and product research and development activities take place under a research and development agreement with the Company. The Company will recognize revenues and related costs as services are performed under such contracts. It is currently expected that most of ASTI's funds will be directed toward continuing the research and development of products based on retinoid and neuroprotective technologies. In addition, ASTI may fund the research and development of pharmaceutical products in therapeutic categories of interest to the Company other than those based on retinoid and neuroprotective technologies, but that complement the Company's product pipeline or otherwise are believed to provide a potential commercialization opportunity for the Company.

The continuing introduction of new products supplied by the Company's

Edgar Filing: ALLERGAN INC - Form 10-K405

research and development efforts and in-licensing opportunities is critical to the success of the Company. There are intrinsic uncertainties associated with the research and development efforts and the regulatory process. There is no assurance that any of the research projects or pending drug marketing approval applications will result in new products that the Company can commercialize. Delays or failures in one or more significant research projects and pending drug marketing approval applications could have a material adverse impact on the future operations of the Company.

COMPETITION

Allergan faces strong competition in all of its markets worldwide. Numerous companies are engaged in the development, manufacture and marketing of health care products competitive with those manufactured by Allergan. Major eye care competitors include Alcon Laboratories, Inc. (a subsidiary of Nestle), Bausch & Lomb and its acquired businesses, Chiron Vision and Storz Ophthalmics, Novartis Ophthalmics, Merck & Co., Inc. and Pharmacia Ophthalmics. These competitors have equivalent or, in most cases, greater resources than Allergan. The Company's skin care business competes against a number of companies, including among others Dermik, a division of Aventis, Galderma, a joint venture between Nestle and L'Oreal, Bristol-Myers Squibb, Schering-Plough Corporation, Johnson & Johnson and Hoffman-La Roche Inc., which all have greater resources than Allergan. In the market for neurotoxins, the Company has two competitors: Beaufour Ipsen, which sells in Europe, Latin America, Asia and New Zealand, and Athena Neurosciences, Inc., a subsidiary of Elan Corporation, PLC, in the United States and Europe. In marketing its products to health care professionals, pharmacy benefits management companies, health care maintenance organizations, and various other national and regional health care providers and managed care entities, the Company competes primarily on the basis of product technology, value-added services and price. The Company believes that it competes favorably in its product markets.

GOVERNMENT REGULATION

Drugs, biologics and medical devices, including IOLs and contact lens care products, are subject to regulation by the FDA, state agencies and, in varying degrees, by foreign health agencies. Government regulation of most of the Company's products generally requires extensive testing of new products and filing applications for approval by the FDA prior to sale in the United States and by foreign health agencies prior to sale as well. The FDA and foreign health agencies review these applications and determine whether the product is safe and effective. The process of developing data to support a premarket application and governmental review is costly and takes many years to complete.

In general, manufacturers of drugs, medical devices and biologicals are operating in a rigorous regulatory environment. The total cost of providing health care services has been and will continue to be subject to review by governmental agencies and legislative bodies in the major world markets, including the United States, which are faced with significant pressure to lower health care costs.

Internationally, the regulation of drugs and medical devices is also complex. In Europe, the Company's products are subject to extensive regulatory requirements. As in the United States, the marketing of medicinal products has for many years been subject to the granting of marketing authorizations by medicine agencies. Particular emphasis is also being placed on more sophisticated and faster procedures for reporting of adverse events to the competent authorities. The European Union ("EU") procedures for the

Edgar Filing: ALLERGAN INC - Form 10-K405

authorization of medicinal products are currently being reviewed by the European Commission and proposals for improving the efficiency of operation of both the mutual recognition and centralized procedure are expected later this year. Additionally, new rules have been introduced or are under discussion in several areas such as the harmonization of clinical research laws and the law relating to orphan drugs and orphan indications.

The EU regulatory regime for medical devices became mandatory in June 1998. It requires that medical devices may only be placed on the market if they do not compromise safety and health when properly installed, maintained and used in accordance with their intended purpose. National laws conforming to this EU legislation regulate the Company's IOLs and contact lens care products under the medical devices regulatory system rather than the more extensive system for medicinal products under which they were formerly regulated. The EU medical device laws require manufacturers to declare that their products conform to the essential regulatory requirements after which the products may be placed on the market bearing CE marking. The manufacturers' quality systems for products in all but the lowest risk classification are also subject to certification and audit by an independent notified body.

In Japan, where the Company currently sells surgical products, consumer eye care products and Botox(R), the regulatory process is equally complex. Premarketing approval and clinical studies are required, as is governmental pricing approval for medical devices and pharmaceuticals. The regulatory regime for pharmaceuticals in Japan has historically been so lengthy and costly that it has been cost prohibitive for Allergan, primarily because Japan required the repetition of all relevant clinical studies in Japan. In the future the process in Japan may become more financially attractive as Japan is in the process of implementing changes to comply with the International Conference on Harmonization, an agreement among Japan, the U.S. and the E.U. to facilitate the registration of drugs utilizing data collected outside of the country. The timeline for completion of these changes and the rules during this period of transition are not certain and in this period registration of pharmaceutical products will remain unpredictable; however, the opportunity to realize value from Allergan's newly developed products in Japan may increase as the environment in Japan moves closer to that of the E.U. and U.S.

9

12

In the United States, a significant percentage of the patients who receive the Company's IOLs are covered by the federal Medicare program. When a cataract extraction with IOL implantation is performed in an ambulatory surgery center ("ASC"), Medicare provides the ASC with a fixed facility fee which includes a recommended \$150 allowance to cover the cost of the IOL. The reimbursement rate for Array(R) multifocal IOLs implanted in ASCs until May 2005 is \$200 after HCFA awarded "new technology IOL" status to the Array(R) multifocal IOL in 2000. When the procedure is performed in a hospital outpatient department, the hospital's reimbursement is determined using a complex formula that blends the hospital's costs with the \$150 allowance paid to ASCs for IOLs that are not "new technology IOLs." For the Array(R) multifocal IOL, Medicare reimburses the hospital based on the actual acquisition cost of the IOL by the hospital.

Proposals to amend Medicare coverage to include pharmaceuticals are currently in debate in the United States. Such coverage could impose price controls on the Company's products. If implemented, price controls could materially and adversely affect the Company's revenues and financial condition.

The Company cannot predict the likelihood or pace of any significant legislative action in these areas, nor can it predict whether or in what form

Edgar Filing: ALLERGAN INC - Form 10-K405

health care legislation being formulated by various governments will be passed. Medicare reimbursement rates are subject to change at any time. The Company also cannot predict with precision what effect such governmental measures would have if they were ultimately enacted into law. However, in general, the Company believes that such legislative activity will likely continue, and the adoption of such measures can be expected to have some impact on the Company's business.

PATENTS, TRADEMARKS AND LICENSES

Allergan owns, or is licensed under, numerous patents relating to its products, product uses and manufacturing processes. It has numerous patents issued in the United States and corresponding foreign patents issued in many of the major countries in which it does business. Allergan believes that its patents and licenses are important to its business, but that with the exception of those relating to Alphagan(R) and Lumigan(TM) ophthalmic solutions, no one patent or license is currently of material importance in relation to its overall sales. Allergan markets its products under various trademarks and considers these trademarks to be valuable because of their contribution to the market identification of the various products.

10

13

ENVIRONMENTAL MATTERS

The Company is subject to federal, state, local and foreign environmental laws and regulations. The Company believes that its operations comply in all material respects with applicable environmental laws and regulations in each country where the Company has a business presence. Although Allergan continues to make capital expenditures for environmental protection, it does not anticipate any significant expenditures in order to comply with such laws and regulations which would have a material impact on the Company's capital expenditures, earnings or competitive position. The Company is not aware of any pending litigation or significant financial obligations arising from current or past environmental practices that are likely to have a material adverse impact on the Company's financial position. There can be no assurance, however, that environmental problems relating to properties owned or operated by the Company will not develop in the future, and the Company cannot predict whether any such problems, if they were to develop, could require significant expenditures on the part of the Company. In addition, the Company is unable to predict what legislation or regulations may be adopted or enacted in the future with respect to environmental protection and waste disposal.

CERTAIN FACTORS AND TRENDS AFFECTING ALLERGAN AND ITS BUSINESSES

Certain statements made by the Company in this report and in other reports and statements released by the Company constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as comments which express the Company's opinions about trends and factors which may impact future operating results. Disclosures that use words such as the Company "believes," "anticipates," "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from expectations. Any such forward-looking statements, whether made in this report or elsewhere, should be considered in context with the various disclosures made by the Company about its businesses including, without limitation, the factors discussed below.

- The pharmaceutical industry and other health care-related industries continue to experience consolidation, resulting in larger, more diversified companies with greater resources than the Company. Among other things, these

Edgar Filing: ALLERGAN INC - Form 10-K405

larger companies can spread their research and development costs over much broader revenue bases than Allergan and can influence customer and distributor buying decisions.

- Until December 2000, the Company was the only manufacturer of an FDA-approved neurotoxin. Another company has now received FDA approval of a neurotoxin. The Company's sales of Botox(R) Purified Neurotoxin Complex could be materially and negatively impacted by this new competition.
- The manufacturing process to create bulk toxin raw material necessary to produce Botox(R) Purified Neurotoxin Complex is technically complicated. Any failure of the Company to maintain an adequate supply of bulk toxin and finished product could result in an interruption in the supply of Botox(R) Purified Neurotoxin Complex and a resulting decrease in sales of the product.
- The Company's Contact Lens Care business continues to be impacted by trends in the contact lens and lens care marketplace, including technological and medical advances in surgical techniques for the correction of vision impairment. Cheaper one-bottle chemical disinfection systems continue to gain popularity among soft contact lens wearers instead of peroxide-based lens care products which historically have been Allergan's strongest family of lens care products. The Company's primary strategy is to focus its sales and marketing resources on aggressive growth of Complete(R)brand Multi-

11

14

Purpose solution which grew faster than its segment on a worldwide basis in 2000. Also, the growing use and acceptance of daily contact lenses and laser-correction procedures, along with the other factors above, could have the effect of reducing demand for lens care products generally. While the Company believes it has established appropriate marketing and sales plans to mitigate the impact of these trends upon its Contact Lens Care business, no assurance can be given in this regard.

- The Company has in the past been, and continues to be, subject to product liability claims. In addition, the Company has in the past and may in the future recall or issue field corrections related to its products due to manufacturing deficiencies, labeling errors or other safety or regulatory reasons. There can be no assurance that the Company will not experience material losses due to product liability claims or product recalls or corrections.
- Sales of the Company's surgical and pharmaceutical products have been and are expected to continue to be impacted by continuing pricing pressures resulting from various government initiatives as well as from the purchasing and operational decisions made by managed care organizations.
- A continuing political issue of debate in the United States is the propriety of expanding Medicare coverage to include pharmaceutical products. If measures to accomplish that coverage become law, and if these measures impose price controls on the Company's products, the Company's revenues and financial condition are likely to be materially and adversely affected.
- The Company collects and pays a substantial portion of its sales and expenditures in currencies other than the U.S. dollar. Therefore, fluctuations in foreign currency exchange rates affect the Company's operating results. The Company can provide no assurance that future exchange rate movements will not have a material adverse effect on the Company's

Edgar Filing: ALLERGAN INC - Form 10-K405

sales, gross profit or operating expenses.

- The Company's business is also subject to other risks generally associated with doing business abroad, such as political unrest and changing economic conditions with countries where the Company's products are sold or manufactured. Management cannot provide assurances that it can successfully manage these risks or avoid their effects.
- Patent protection is generally important in the pharmaceutical industry. Therefore, Allergan's future financial success may depend in part on obtaining patent protection for technologies incorporated into products. No assurance can be given that patents will be issued covering any products, or that any existing patents or patents issued in the future will be of commercial benefit. In addition, it is impossible to anticipate the breadth or degree of protection that any such patents will afford, and there can be no assurance that any such patents will not be successfully challenged in the future. If the Company is unsuccessful in obtaining or preserving patent protection, or if any products rely on unpatented proprietary technology, there can be no assurance that others will not commercialize products substantially identical to such products. Furthermore, although Allergan has a corporate policy not to infringe the valid and enforceable patents of others, Allergan cannot provide assurances that its products will not infringe patents held by third parties. In such event, licenses from such third parties may not be available or may not be available on commercially attractive terms. Please see Item 3 on page 13 for information on current patent litigation.
- The Company sells its pharmaceutical products primarily through wholesalers. Wholesaler purchases may exceed customer demand, resulting in reduced wholesaler purchases in later quarters. The Company can give no assurances that wholesaler purchases will not decline as a result of this potential excess buying.

12

15

- Future performance of the Company will be affected by the introduction of new products such as Lumigan(TM) and FDA approval of new indications for current products such as Botox(R) Purified Neurotoxin Complex. The Company has allocated significant resources to the development and introduction of new products and indications. The successful development, regulatory approval and market acceptance of the products and indications cannot be assured.
- There are intrinsic uncertainties associated with research & development efforts and the regulatory process both of which are discussed in greater details in the "Research and Development" and the "Government Regulation" sections of this report on Form 10-K, which are incorporated herein by reference.

ITEM 2. PROPERTIES

Allergan's operations are conducted in owned and leased facilities located throughout the world. The Company believes its present facilities are adequate for its current needs. Its headquarters and primary administrative and research facilities are located in Irvine, California. The Company has three additional facilities in California, two for raw material support (one leased and one owned) and one leased administrative facility. The Company owns one facility in Texas for manufacturing and warehousing, and the Company operates two facilities in Puerto Rico for manufacturing and warehousing. One of the Puerto Rico facilities is leased and the other is owned. As previously

Edgar Filing: ALLERGAN INC - Form 10-K405

announced, the Company intends to close the facility that it owns in 2001.

Outside of the United States and Puerto Rico, the Company owns and operates three manufacturing and warehousing facilities located in Brazil, Ireland and China. Other material facilities include one owned facility for administration and warehousing in Argentina; leased warehouse facilities in Mexico and Japan; leased administrative facilities in Australia, Brazil, Canada, France, Germany, Hong Kong, Ireland, Italy, Japan, Spain and the United Kingdom; and one leased facility in Japan used for administration and research and development.

ITEM 3. LEGAL PROCEEDINGS

The Company and its subsidiaries are involved in various litigation and claims arising in the ordinary course of business which Allergan considers to be normal in view of the size and nature of its business.

On March 1, 2001, after concluding that Pharmacia Corporation planned to file a patent infringement lawsuit against Allergan regarding the investigational glaucoma drug, Lumigan(TM), Allergan filed a declaratory relief lawsuit against Pharmacia (and related entities) in United States District Court for the District of Delaware. In the lawsuit, Allergan asked the court to issue a ruling that Lumigan(TM) does not infringe certain patents owned or controlled by Pharmacia and also that such patents are not valid. On March 21, 2001, Pharmacia filed an answer to the complaint, denying Allergan's allegations. Pharmacia and Columbia University also filed a counterclaim against Allergan, alleging that Allergan infringes the same two patents that Allergan identified in its complaint. See "Certain Factors and Trends Affecting Allergan and its Businesses" for further information about the risks and uncertainties associated with patents.

Although the ultimate outcome of any pending litigation and claims cannot be precisely ascertained at this time, Allergan believes that the liability, if any, resulting from the aggregate amount of uninsured damages for outstanding lawsuits, investigations and asserted claims will not have a material adverse effect on its consolidated financial position and results of operation. However, in view of the unpredictable nature of such matters, no assurances can be given in this regard.

13

16

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Company did not submit any matter during the fourth quarter of the fiscal year covered by this report to a vote of security holders, through the solicitation of proxies or otherwise.

ITEM I-A. EXECUTIVE OFFICERS OF ALLERGAN, INC.

The executive officers of the Company and their ages as of March 1, 2001 are as follows:

David E.I. Pyott	47	President and Chief Executive Officer
F. Michael Ball	45	Corporate Vice President and President, North America Region and Global Eye Rx Business

Edgar Filing: ALLERGAN INC - Form 10-K405

Eric K. Brandt	38	Corporate Vice President, Chief Financial Officer and President, Global Consumer Eye Care Business (Principal Financial Officer)
David A. Fellows	44	Corporate Vice President and President, Asia Pacific Region
James M. Hindman, CPA	40	Senior Vice President and Controller (Principal Accounting Officer)
Lester J. Kaplan, Ph.D.	50	Corporate Vice President and President, Research and Development and Global BOTOX (R)
George M. Lasezkay, Pharm.D., J.D.	49	Corporate Vice President, Corporate Development
Nelson R. A. Marques	50	Corporate Vice President and President, Latin America Region
James V. Mazzo	43	Corporate Vice President and President, Europe/Africa/Middle East Region and Global Surgical Business
Jacqueline Schiavo	52	Corporate Vice President, Worldwide Operations
Francis R. Tunney, Jr.	53	Corporate Vice President - Administration and Secretary

Officers are appointed by and hold office at the pleasure of the Board of Directors.

Mr. Pyott became President and Chief Executive Officer in January 1998. Previously, he was head of the Nutrition Division and a member of the executive committee of Novartis AG from 1995 until December 1997. From 1992 to 1995 Mr. Pyott was President and Chief Executive Officer of Sandoz Nutrition Corp., Minneapolis,

14

17

Minnesota and General Manager of Sandoz Nutrition, Barcelona, Spain from 1990 to 1992. Prior to that Mr. Pyott held various positions within Sandoz Nutrition group from 1980.

Mr. Ball has been Corporate Vice President and President, North America Region and Global Eye Rx Business since May 1998 and prior to that was Corporate Vice President and President, North America Region since April 1996. He joined the Company in 1995 as Senior Vice President, U.S. Eye Care after 12 years with Syntex Corporation, where he held a variety of positions including President, Syntex Inc. Canada and Senior Vice President, Syntex Laboratories.

Mr. Brandt has been Corporate Vice President and Chief Financial Officer since May 1999 and in January 2001 he also assumed the duties of President, Global Consumer Eye Care Business. Prior to joining the Company, Mr. Brandt held various positions with the Boston Consulting Group ("BCG") from 1989, culminating in Vice President and Partner, and a senior member of the BCG Health Care practice. While at BCG, Mr. Brandt was involved in high level consulting

Edgar Filing: ALLERGAN INC - Form 10-K405

engagements with top global pharmaceutical, managed care and medical device companies, focusing on corporate finance, shareholder value and post-merger integration. Mr. Brandt joined the Company in 1999.

Mr. Fellows has been Corporate Vice President and President of the Asia Pacific Region since June 1997 and prior thereto, was Senior Vice President, U.S. Eye Care Marketing since June 1996. From 1993 to 1996, he was Senior Vice President, Therapeutics Strategic Marketing, and from 1991 until 1993, he was Vice President, Pharmaceuticals Strategic Marketing. Mr. Fellows joined the Company in 1980.

Mr. Hindman has been Senior Vice President and Controller since January 2000 and prior thereto was Vice President, Financial Planning & Analysis since February 1997. Prior to that he served 12 years in a variety of positions at the Company, including Plant Controller, Director of Manufacturing Planning and Reporting, Director of Finance (Northwest Europe), and Assistant Corporate Controller. Mr. Hindman first joined the Company in 1984.

Dr. Kaplan has been Corporate Vice President and President, Research and Development and Global BOTOX(R) since May 1998 and had been Corporate Vice President, Science and Technology since July 1996. From 1992 until 1996, he was Corporate Vice President, Research and Development. He had been Senior Vice President, Pharmaceutical Research and Development since 1991 and Senior Vice President, Research and Development since 1989. Dr. Kaplan first joined the Company in 1983.

Dr. Lasezkay has been Corporate Vice President, Corporate Development since October 1998 and had been Vice President, Corporate Development since July 1996. He had been Assistant General Counsel of the Company since 1995 and Senior Counsel to the Company since 1989 when he first joined the Company.

Mr. Marques has been Corporate Vice President and President, Latin America Region since October 1998. Prior to that he served 18 years with Alcon, where he held a variety of positions, including President, Alcon Laboratorios do Brasil Ltda. from 1994 until 1998. Mr. Marques joined the Company in 1998.

Mr. Mazzo has been Corporate Vice President and President, Europe/Africa/Middle East Region since April 1998 and in January 2001 he also assumed the duties of President, Global Surgical Business. From May 1998 to January 2001, Mr. Mazzo was also the President of Global Lens Care Products. He had been Senior Vice President Eyecare/Rx Sales and Marketing, U.S. since June 1997 during which time he served as acting President Europe/Africa/Middle East Region from October - December 1997. Prior

15

18

to that, he served 11 years in a variety of positions at the Company, including Director, Marketing (Canada), Vice President and Managing Director (Italy) and Senior Vice President Northern Europe. Mr. Mazzo first joined the Company in 1980.

Ms. Schiavo has been Corporate Vice President, Worldwide Operations since 1992. She was Senior Vice President, Operations from 1991 and Vice President, Operations from 1989. Ms. Schiavo first joined the Company in 1980.

Mr. Tunney has been Corporate Vice President - Administration, and Secretary since January 2001. Prior thereto he served as Corporate Vice President-Administration, General Counsel and Secretary of the Company since 1998. Since 1998 he has also served as the Company's Chief Ethics Officer. From 1991 through 1998 he was Corporate Vice President, General Counsel and Secretary

Edgar Filing: ALLERGAN INC - Form 10-K405

and prior thereto was Senior Vice President, General Counsel and Secretary from 1989 through 1991. Mr. Tunney first joined SmithKline Beckman Corporation, the Company's former parent, in 1979.

16

19

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The section entitled "Market Prices of Common Stock and Dividends" on page A-49 of the Proxy Statement is incorporated herein by reference.

On November 1, 2000, the Company issued and sold \$657,451,000 aggregate principal amount at maturity of Liquid Yield Option(TM) Notes due November 1, 2020 ("LYONs") at an initial offering price of \$608.41 per \$1,000 face amount. The LYONs were sold by Merrill Lynch & Co. to qualified institutional buyers in transactions exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Rule 144A promulgated thereunder. The discount to Merrill Lynch was \$15.21 per \$1,000 aggregate principal amount at maturity of the LYONs. Holders may convert their LYONs at any time on or before the maturity date, unless the LYONs have been previously redeemed or purchased, into 5.7615 shares of Allergan Common Stock per LYON.

Allergan subsequently registered the LYONs pursuant to Registration Statement 333-50524, effective December 8, 2000.

ITEM 6. SELECTED FINANCIAL DATA

The table entitled "Selected Financial Data" on page A-48 of the Proxy Statement is incorporated herein by reference.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations for the Three-Year Period Ended December 31, 2000" on pages A-2 to A-12 of the Proxy Statement is incorporated herein by reference.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The section entitled "Quantitative and Qualitative Market Risk Factors" on pages A-13 to A-17 of the Proxy Statement is incorporated herein by reference.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements, including the notes thereto, included on pages A-18 to A-44 of the Proxy Statement, together with the sections entitled "Independent Auditors' Report" and "Quarterly Results (Unaudited)" of the Proxy Statement included on pages A-46 and A-47, respectively, are incorporated herein by reference.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF ALLERGAN, INC.

Information under this Item is included on pages 2-4 of the Proxy Statement in the section entitled "Election of Directors" and is incorporated herein by reference. Information with respect to executive officers is included on pages 14-16 of this Form 10-K.

The information required by Item 405 of Regulation S-K is included on page 8 of the Proxy Statement under the section entitled "Section 16(a) Beneficial Ownership Reporting Compliance" and is incorporated herein by reference.

ITEM 11. EXECUTIVE COMPENSATION

The section entitled "Executive Compensation," and the subsection entitled "Director Compensation" included in the Proxy Statement on pages 15-23 and pages 6-7, respectively, are incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The common stock information in the section entitled "Security Ownership of Certain Beneficial Owners and Management" on pages 13-14 of the Proxy Statement is incorporated herein by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

The sections entitled "Other Matters" and "Compensation Committee Interlocks and Insider Participation" on page 7 and page 24, respectively, of the Proxy Statement are incorporated herein by reference.

PART IV

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

(a) Index to Financial Statements*

PAGE(S) IN
PROXY STATEMENT

1. Financial Statements included in Part II of this report:

Independent Auditors' Report A-46

Consolidated Balance Sheets at December 31, 2000 and
December 31, 1999 A-18

Edgar Filing: ALLERGAN INC - Form 10-K405

Consolidated Statements of Operations for Each of the Years
in the Three Year Period Ended December 31, 2000 A-19

Consolidated Statements of Stockholders' Equity for
Each of the Years in the Three Year Period
Ended December 31, 2000 A-20

Consolidated Statements of Cash Flows for Each of the Years
in the Three Year Period Ended December 31, 2000 A-21

Notes to Consolidated Financial StatementsA-22 to A-44

* Incorporated by reference from the indicated pages of the Company's Proxy
Statement filed with the Securities and Exchange Commission on March 23,
2001.

2. Schedules Supporting the Consolidated Financial Statements:

PAGE IN
THIS REPORT

Schedule numbered in accordance with Rule 5-04 of
Regulation S-X:

II Valuation and Qualifying Accounts..... S-8

All other schedules have been omitted for the reason that the required
information is presented in financial statements or notes thereto, the
amounts involved are not significant or the schedules are not
applicable.

(b) Reports on Form 8-K

On November 1, 2000, the Company filed a Current Report on Form 8-K
with the Securities and Exchange Commission. The filing related to
Allergan's issuance of \$657,451,000 in aggregate principal amount at
maturity of Liquid Yield Option(TM) Notes due November 1, 2020 (Zero
Coupon -- Subordinated) at an initial offering price of \$608.41 per
\$1,000 face amount of LYONs.

(c) Item 601 Exhibits

Reference is made to the Index of Exhibits beginning at page S-3 of
this report.

(d) Other Financial Statements

There are no financial statements required to be filed by Regulation
S-X which are excluded from the Proxy Statement by Rule 14 a-3(b) (1).

Edgar Filing: ALLERGAN INC - Form 10-K405

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 23, 2001

ALLERGAN, INC.

By /S/ DAVID E.I. PYOTT

David E.I. Pyott
President, Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the date indicated.

Date: March 23, 2001

By /S/ DAVID E.I. PYOTT

David E.I. Pyott
President, Chief Executive Officer

Date: February 26, 2001

By /S/ ERIC K. BRANDT

Eric K. Brandt
Corporate Vice President,
Chief Financial Officer and President,
Global Consumer Eye Care Business
(Principal Financial Officer)

Date: March 23, 2001

By /S/ JAMES M. HINDMAN

James M. Hindman
Senior Vice President and Controller
(Principal Accounting Officer)

Date: March 1, 2001

By /S/ HERBERT W. BOYER

Herbert W. Boyer, Ph.D.,
Chairman of the Board

Date: February 23, 2001

By /S/ RONALD M. CRESSWELL

Ronald M. Cresswell, Director

Date: March 5, 2001

By /S/ HANDEL E. EVANS

Handel E. Evans, Director

Date: March 23, 2001

By /S/ MICHAEL R. GALLAGHER

Michael R. Gallagher, Director

Date: March 23, 2001

By /S/ WILLIAM R. GRANT

William R. Grant, Director

Edgar Filing: ALLERGAN INC - Form 10-K405

23

S-1

Date: March 23, 2001

By /S/ GAVIN S. HERBERT

Gavin S. Herbert, Director and
Chairman Emeritus

Date: March 6, 2001

By /S/ LESTER J. KAPLAN

Lester J. Kaplan, Ph.D., Director

Date: March 23, 2001

By /S/ KAREN R. OSAR

Karen R. Osar, Director

Date: March 23, 2001

By /S/ LOUIS T. ROSSO

Louis T. Rosso, Director

Date: March 23, 2001

By /S/ LEONARD D. SCHAEFFER

Leonard D. Schaeffer, Director

Date: March 23, 2001

By /S/ ANTHONY H. WILD

Anthony H. Wild, Director

24

S-2

INDEX OF EXHIBITS

EXHIBIT
NUMBER

DESCRIPTION

- | EXHIBIT
NUMBER | DESCRIPTION |
|-------------------|--|
| 3.1 | Restated Certificate of Incorporation of the Company as filed with the State of Delaware on May 22, 1989 (incorporated by reference to Exhibit 3.1 to Registration Statement on Form S-1 No. 33-28855, filed May 24, 1989) |
| 3.2 | Certificate of Amendment of Certificate of Incorporation of Allergan, Inc. (incorporated by reference to the Company's Report on Form 10-Q for the Quarter ended June 30, 2000) |

Edgar Filing: ALLERGAN INC - Form 10-K405

- 3.3 Bylaws of the Company (incorporated by reference to Exhibit 3 to the Company's Report on Form 10-Q for the Quarter ended June 30, 1995)
- 3.4 First Amendment to Allergan, Inc. Bylaws (incorporated by reference to Exhibit 3.1 to the Company's Report on Form 10-Q for the Quarter ended September 24, 1999)
- 4.1 Certificate of Designations of Series A Junior Participating Preferred Stock as filed with the State of Delaware on February 1, 2000 (incorporated by reference to Exhibit 4.1 to the Company's Report on Form 10-K for the Fiscal Year ended December 31, 1999)
- 4.2 Rights Agreement, dated January 25, 2000, between Allergan, Inc. and First Chicago Trust Company of New York (incorporated by reference to Exhibit 4 to the Company's Current Report on Form 8-K filed on January 28, 2000)
- 4.3 Indenture between the Company and BankAmerica National Trust Company (incorporated by reference to Exhibit 4 filed with the Company's Registration Statement 33-69746)
- 4.4 Indenture, dated as of November 1, 2000, between the Company and U.S. Trust National Association (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on November 1, 2000)
- 4.5 Registration Rights Agreement, dated November 1, 2000, between the Company and Merrill Lynch & Co., Merrill Lynch, Pierce Fenner & Smith Incorporated (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K, filed on November 1, 2000)
- 10.1 Form of director and executive officer Indemnity Agreement (incorporated by reference to Exhibit 10.4 to the Company's Report on Form 10-K for the Fiscal Year ended December 31, 1992)

S-3

25

EXHIBIT NUMBER -----	DESCRIPTION -----
10.2	Form of Allergan change in control severance agreement (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on January 28, 2000)*
10.3	Allergan, Inc. 1989 Nonemployee Director Stock Plan, as amended and restated (incorporated by reference to Exhibit B to the Company's Proxy Statement filed on March 16, 2000)*
10.4	Allergan, Inc. Deferred Directors' Fee Program amended and restated as of November 15, 1999 (incorporated by reference to Exhibit 4 to Registration Statement on Form S-8 No. 333-94155, filed January 6, 2000)*
10.5	Allergan, Inc. 1989 Incentive Compensation Plan, as amended and restated

Edgar Filing: ALLERGAN INC - Form 10-K405

- 10.6 Allergan, Inc. Employee Stock Ownership Plan (restated 2000)
(incorporated by reference to Exhibit 10.1 to the Company's Report on Form 10-Q for the Quarter ended June 30, 2000)
- 10.7 First Amendment to Allergan, Inc. Employee Stock Ownership Plan
(restated 2000)
- 10.8 Allergan, Inc. Savings and Investment Plan (restated 2000)
(incorporated by reference to Exhibit 10.3 to the Company's Report on Form 10-Q for the Quarter ended June 30, 2000)
- 10.9 First Amendment to Allergan, Inc. Savings and Investment Plan
(restated 2000)
- 10.10 Restated Allergan, Inc. Pension Plan (incorporated by reference to Exhibit 10.3 to the Company's Report on Form 10-Q for the Quarter ended March 31, 1996)
- 10.11 First Amendment to the Allergan, Inc. Pension Plan (incorporated by reference to Exhibit 10.14 to the Company's Report on Form 10-K for the Fiscal Year ended December 31, 1997)
- 10.12 Second Amendment to the Allergan, Inc. Pension Plan (incorporated by reference to Exhibit 10.2 to the Company's Report on Form 10-Q for the Quarter ended June 26, 1998)
- 10.13 Third Amendment to the Allergan, Inc. Pension Plan (incorporated by reference to Exhibit 10.2 to the Company's Report on Form 10-Q for the Quarter ended September 24, 1999)
- 10.14 Fourth Amendment to the Allergan, Inc. Pension Plan (incorporated by reference to Exhibit 10.10 to the Company's Current Report on Form 8-K filed on January 28, 2000)

S-4

26

EXHIBIT NUMBER -----	DESCRIPTION -----
10.15	Restated Allergan, Inc. Supplemental Retirement Income Plan (incorporated by reference to Exhibit 10.5 to the Company's Report on Form 10-Q for the Quarter ended March 31, 1996)*
10.16	First Amendment to Allergan, Inc. Supplemental Retirement Income Plan (incorporated by reference to Exhibit 10.4 to the Company's Report on Form 10-Q for the Quarter ended September 24, 1999)*
10.17	Second Amendment to Allergan, Inc. Supplemental Retirement Income Plan (incorporated by reference to Exhibit 10.12 to the Company's Current Report on Form 8-K filed on January 28, 2000)*
10.18	Restated Allergan, Inc. Supplemental Executive Benefit Plan (incorporated by reference to Exhibit 10.6 to the Company's Report on Form 10-Q for the Quarter ended March 31, 1996)*

Edgar Filing: ALLERGAN INC - Form 10-K405

- 10.19 First Amendment to Allergan, Inc. Supplemental Executive Benefit Plan (incorporated by reference to Exhibit 10.3 to the Company's Report on Form 10-Q for the Quarter ended September 24, 1999)*
- 10.20 Second Amendment to Allergan, Inc. Supplemental Executive Benefit Plan (incorporated by reference to Exhibit 10.11 to the Company's Current Report on Form 8-K filed on January 28, 2000)*
- 10.21 Allergan, Inc. Executive Bonus Plan (incorporated by reference to Exhibit C to the Company's Proxy Statement dated March 23, 1999, filed in definitive form on March 22, 1999) *
- 10.22 First Amendment to Allergan, Inc. Executive Bonus Plan (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on January 28, 2000)*
- 10.23 Allergan, Inc. 2001 Management Bonus Plan*
- 10.24 Allergan, Inc. Executive Deferred Compensation Plan amended and restated, effective January 1, 2000 (incorporated by reference to Exhibit 4 to Registration Statement on Form S-8 No. 333-94157, filed January 6, 2000)*
- 10.25 First Amendment to Allergan, Inc. Executive Deferred Compensation Plan (restated 2000) (incorporated by reference to Exhibit 10.5 to the Company's Report on 10-Q for the Quarter ended June 30, 2000) *
- 10.26 Allergan, Inc. Premium Priced Stock Option Plan (incorporated by reference to Exhibit B to the Company's Proxy Statement filed on March 23, 2001)*

S-5

27

EXHIBIT NUMBER -----	DESCRIPTION -----
10.27	Distribution Agreement dated March 4, 1994 between Allergan, Inc. and Merrill Lynch & Co. and J.P. Morgan Securities Inc. (incorporated by reference to Exhibit 10.14 to the Company's Report on Form 10-K for the fiscal year ended December 31, 1993)
10.28	\$250,000,000 Credit Agreement dated as of December 22, 1993 and amended and restated as of May 10, 1996 among the Company, as Borrower and Guarantor, the Eligible Subsidiaries Referred to Therein, the Banks Listed Therein, Morgan Guaranty Trust Company of New York, as Agent and Bank of America National Trust and Savings Association, as Co-Agent (the "Credit Agreement") (incorporated by reference to Exhibit 10.7 to the Company's Report on Form 10-Q for the Quarter ended March 31, 1996)
10.29	Amendment No. 1 to the Credit Agreement, dated March 5, 1998 (incorporated by reference to Exhibit 10.1 to the Company's Report on Form 10-Q for the Quarter ended June 26, 1998)
10.30	Amended and Restated Credit Agreement, dated March 24, 1998

Edgar Filing: ALLERGAN INC - Form 10-K405

- 10.31 Amendment No. 1 to the Amended and Restated Credit Agreement, dated December 8, 2000
- 10.32 Letter Agreement between Allergan, Inc. and William C. Shepherd dated September 27, 1997 (incorporated by reference to Exhibit 10.22 to the Company's Report on Form 10-K for the Fiscal Year ended December 31, 1997)*
- 10.33 Technology License Agreement dated as of March 6, 1998 among Allergan, Inc. and certain of its affiliates and Allergan Specialty Therapeutics, Inc. ("ASTI") (incorporated by reference to Exhibit 10.23 to the Company's Report on Form 10-K for the Fiscal Year ended December 31, 1997)
- 10.34 Research and Development Agreement dated as of March 6, 1998 between Allergan, Inc. and ASTI (incorporated by reference to Exhibit 10.2 to the Company's Report on Form 10-Q for the Quarter ended March 27, 1998)
- 10.35 License Option Agreement dated as of March 6, 1998 between Allergan, Inc. and ASTI (incorporated by reference to Exhibit 10.25 to the Company's Report on Form 10-K for the Fiscal Year ended December 31, 1997)
- 10.36 Distribution Agreement dated as of March 6, 1998 between Allergan, Inc. and ASTI (incorporated by reference to Exhibit 10.26 to the Company's Report on Form 10-K for the Fiscal Year ended December 31, 1997)

S-6

28

EXHIBIT
NUMBER

DESCRIPTION

- | EXHIBIT
NUMBER
----- | DESCRIPTION
----- |
|----------------------------|---|
| 21 | List of Subsidiaries of the Company |
| 23 | Report and consent of KPMG LLP to the incorporation of their reports herein to Registration Statements Nos. 33-29527, 33-29528, 33-44770, 33-48908, 33-66874, 333-09091, 333-04859, 333-25891, 33-55061, 33-69746, 333-64559, 333-70407, 333-94155, 333-94157, 333-43580, 333-43584, and 333-50524. |

* Management contract or compensatory plan, contract or arrangement required to be filed as an exhibit pursuant to Item 14(c) of Form 10-K.

S-7

29

SCHEDULE II

ALLERGAN, INC.
VALUATION AND QUALIFYING ACCOUNTS

Edgar Filing: ALLERGAN INC - Form 10-K405

YEARS ENDED DECEMBER 31, 2000, 1999, AND 1998
(IN MILLIONS)

	BALANCE AT BEGINNING OF YEAR -----	ADDITIONS -----	DEDUCTIONS -----	BALANCE AT END OF YEAR -----
2000	\$5.4 ----	\$0.1(a) -----	\$1.5(b) -----	\$4.0 ----
1999	\$6.7 ----	\$0.3(a) -----	\$1.6(b) -----	\$5.4 ----
1998	\$6.8 ----	\$1.1(a) -----	\$1.2(b) -----	\$6.7 ----

(a) Provision charged to earnings.
(b) Accounts written off.

S-8

30

INDEX OF EXHIBITS

EXHIBIT NUMBER -----	DESCRIPTION -----
10.5	Allergan, Inc. 1989 Incentive Compensation Plan, as amended and restated
10.7	First Amendment to Allergan, Inc. Employee Stock Ownership Plan (restated 2000)
10.9	First Amendment to Allergan, Inc. Savings and Investment Plan (restated 2000)
10.23	Allergan, Inc. 2001 Management Bonus Plan*
10.30	Amended and Restated Credit Agreement, dated March 24, 1998
10.31	Amendment No. 1 to the Amended and Restated Credit Agreement, dated December 8, 2000
21	List of Subsidiaries of the Company
23	Report and consent of KPMG LLP to the incorporation of their reports herein to Registration Statements Nos. 33-29527, 33-29528, 33-44770, 33-48908, 33-66874, 33-09091, 33-04859, 33-25891, 33-55061,

Edgar Filing: ALLERGAN INC - Form 10-K405

33-69746, 333-64559, 333-70407, 333-94155, 333-94157, 333-43580,
333-43584, and 333-50524.

* Management contract or compensatory plan, contract or arrangement required to be filed as an exhibit pursuant to Item 14(c) of Form 10-K.